
The first new Alzheimer’s drug in nearly two decades was approved by the U.S. Food and Drug Administration on Monday, despite opposition from the agency’s own independent advisory committee and some experts who said there wasn’t enough proof the drug could actually help patients. In clinical trials, aducanumab (Aduhelm) showed a 22% reduction in the… read on > read on >